The Use of Molecular Genetics to Refine Prognosis in Acute Myeloid Leukemia

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

(2013) V. I. Gaidzik et al.   BLOOD

Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients

(2013) N. Rapin et al.   BLOOD

CEBPAdouble-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases withTET2andGATA2alterations impacting prognosis

(2013) Vera Grossmann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia:miR-155Upregulation Independently Identifies High-Risk Patients

(2013) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

(2013) Maxime Janin et al.   JOURNAL OF CLINICAL ONCOLOGY

The promise of whole-exome sequencing in medical genetics

(2013) Bahareh Rabbani et al.   JOURNAL OF HUMAN GENETICS

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

MicroRNA and piRNA Profiles in Normal Human Testis Detected by Next Generation Sequencing

(2013) Qingling Yang et al.   PLoS One

KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement

(2012) Hee-Jin Kim et al.   ANNALS OF HEMATOLOGY

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

(2012) M.-C. Lo et al.   BLOOD

A novel hierarchical prognostic model of AML solely based on molecular mutations

(2012) V. Grossmann et al.   BLOOD

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

(2012) P. Yan et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

RUNX1Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

(2012) Jason H. Mendler et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group

(2012) Verena I. Gaidzik et al.   JOURNAL OF CLINICAL ONCOLOGY

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

(2012) A Fasan et al.   LEUKEMIA

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

(2012) S Schnittger et al.   LEUKEMIA

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

(2011) M. B. Treppendahl et al.   BLOOD

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications

(2011) H.-A. Hou et al.   BLOOD

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

(2011) K. H. Metzeler et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

DNA methylation as a pathogenic event and as a therapeutic target in AML

(2011) Till Schoofs et al.   CANCER TREATMENT REVIEWS

Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia

(2011) Claudia Haferlach et al.   GENES CHROMOSOMES & CANCER

Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value

(2011) M. Pratcorona et al.   HAEMATOLOGICA

Adverse Prognostic Impact of Abnormal Lesions Detected by Genome-Wide Single Nucleotide Polymorphism Array–Based Karyotyping Analysis in Acute Myeloid Leukemia With Normal Karyotype

(2011) Jun Ho Yi et al.   JOURNAL OF CLINICAL ONCOLOGY

RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

(2011) Verena I. Gaidzik et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2011) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML

(2011) H J M de Jonge et al.   LEUKEMIA

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response

(2011) J M Brandwein et al.   LEUKEMIA

Landscape of TET2 mutations in acute myeloid leukemia

(2011) S Weissmann et al.   LEUKEMIA

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1

(2010) S. Lugthart et al.   BLOOD

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

(2010) C. L. Green et al.   BLOOD

Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells

(2010) A. Hofmann et al.   BLOOD

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations

(2010) W.-C. Chou et al.   BLOOD

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

(2010) E. Taskesen et al.   BLOOD

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

(2010) S. Schnittger et al.   BLOOD

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

(2010) Maria E. Figueroa et al.   CANCER CELL

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

HighEVI1Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities

(2010) Stefan Gröschel et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance ofCEBPAMutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of DoubleCEBPAMutations and the Interaction WithFLT3andNPM1Mutations

(2010) Claire L. Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A

(2010) Richard F. Schlenk et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

(2010) Torsten Haferlach et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia

(2010) Anjali S. Advani et al.   LEUKEMIA RESEARCH

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

(2009) L. Bullinger et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

(2009) T Pabst et al.   BRITISH JOURNAL OF CANCER

New Lesions Detected by Single Nucleotide Polymorphism Array–Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia

(2009) Ramon V. Tiu et al.   JOURNAL OF CLINICAL ONCOLOGY

Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia

(2009) Arati V. Rao et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

(2009) Annika Dufour et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances

(2009) T. LaFramboise   NUCLEIC ACIDS RESEARCH

MicroRNA expression in acute myeloid leukemia

(2009) Guido Marcucci et al.   Current Hematologic Malignancy Reports

RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia

(2008) W.-I. Kim et al.   BLOOD

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication

(2008) S. P. Whitman et al.   BLOOD

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML

(2008) L. Bullinger et al.   BLOOD

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

(2008) K. H. Metzeler et al.   BLOOD

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

(2008) R. Garzon et al.   BLOOD

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

(2008) R. G.W. Verhaak et al.   HAEMATOLOGICA

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

(2008) C Haferlach et al.   LEUKEMIA

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

(2008) Timothy J. Ley et al.   NATURE

Mapping and quantifying mammalian transcriptomes by RNA-Seq

(2008) Ali Mortazavi et al.   NATURE METHODS

RNA-Seq: a revolutionary tool for transcriptomics

(2008) Zhong Wang et al.   NATURE REVIEWS GENETICS

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE

MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Guido Marcucci et al.   NEW ENGLAND JOURNAL OF MEDICINE